Zara Baloch, Review Editor | Editorial Board Member at OncoDaily, Director Quantitative Research and Meta Analysis, Digital Education Manager and Host at MedNews Week, shared on LinkedIn:
“What is actually changing in how we diagnose and treat primary brain tumors?
We recently featured Dr. Morana Vojnic, MD, MBA, Director of Neuro-Oncology at Rutgers Cancer Institute and System Leader for Neuro-Oncology at RWJBarnabas Health, in this MedNews Week × OncoDaily discussion.
Dr. Vojnic shares her perspective on the rapidly evolving role of molecular testing in gliomas – from IDH mutations and 1p/19q co-deletion to targeted therapies, liquid biopsy, AI in neuro-oncology, and the challenges that remain in high-grade disease.
A thoughtful conversation on where precision neuro-oncology is heading and how molecular profiling is increasingly shaping clinical decision-making.”
Watch the full discussion here
To which Ayesha Junaid, Final-Year MBBS Student at Dow Medical College, Clinical Researcher, MedNews Week Team Member, added:
“A brain tumor diagnosis is no longer defined by what we see under the microscope alone.
Molecular alterations are increasingly changing how gliomas are classified, understood, and treated and that shift opens up an entirely different conversation around targeted therapy, liquid biopsy, and AI.
Dr. Morana Vojnic, MD, MBA takes us through where precision neuro-oncology stands today and what may come next.”
Other articles about Brain Tumors and neuro-oncology on OncoDaily.